Year: 2025
Type: article
Abstract: This article, centered on precision therapy, argues that traditional disease-centered clinical trials are flawed with prolonged cycles, insufficient early-phase samples, and inflexible protocols, thus proposing the concept of "clinical trial re-innovation." It elaborates that this re-innovation, driven by biomarker technology, multi-arm multi-stage designs, and improved trial flexibility, is realized through innovative designs like basket, umbrella, and platform trials, and explores their application in multiple diseases with cases, aiming to advance precise and efficient clinical research and improve patient outcomes.
Source: Cancer Innovation
DOI: 10.1002/cai2.70028
Authors: Shenglan Li, Jiachen Wang, Zhuang Kang, Xun Kang, Feng Chen, Wenbin Li
Institutions: Capital Medical University, Beijing Tian Tan Hospital
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W4414487229